Pathologists have been noting nerve fibers threaded through solid tumors for years. Breast, prostate, pancreatic, and ovarian tumors all show it, denser innervation tends to track with worse outcomes, and nobody has established in a living animal how the nerves got there.
The assumption, based largely on cell culture work, was that the cancer cells themselves emitted the signal. A team at the University of Oklahoma tested this in mice and found the assumption was wrong. The signal comes from immune cells that the tumor recruits first.
The study in Cell Death and Differentiation, led by Jumana Abbadi with senior author Maureen Cox, reports that macrophages within triple-negative breast tumors secrete brain-derived neurotrophic factor, and that removing this single source prevents nerves from growing in and stops the tumor from growing at all.
The Missing Link Was Not the Tumor Cell
BDNF is best known as a brain protein. It supports neuronal survival and drives axon extension, and it has been on the tumor-innervation list for some time alongside other neurotrophic factors thought to be released by tumor cells.
What had never been demonstrated in a living animal was which cell actually supplies it. The Oklahoma team pointed at macrophages, on the reasoning that during ordinary wound healing, macrophages are the primary source of neurotrophins, and macrophages are abundant in triple-negative breast tumors.
The setup was direct. Syngeneic Py230 mouse triple-negative breast cancer cells were transplanted into intact mice and into mice engineered to lack immune-derived BDNF, which isolates the immune contribution from anything the cancer cells produce themselves.
Take the Macrophages Out and the Tumor Does Not Grow
In mice lacking immune-derived BDNF, the transplanted tumors could not grow. Depleting macrophages from the tumor microenvironment compromised innervation.
The confirming experiment ran the other direction. Transplanting normal bone-marrow-derived macrophages into the BDNF-deficient mice restored both innervation and tumor growth. The authors describe macrophage-derived BDNF as both necessary and sufficient for axonogenesis in this model, a strong claim that the design supports.
"Macrophages are the critical source for drawing nerves into the tumor," Cox said. "Although macrophages typically play a positive role in the body, they are facilitating a negative function in this scenario of breast cancer."
Sensory nerves specifically, rather than nerves in general, appeared to be what the growth depended on. Blocking BDNF signaling pharmacologically diminished both innervation and tumor growth, which points at the BDNF and TrkB receptor axis as the pressure point.
That last point has generated some overheated framing. Cox told the university's news office that "it looks really promising that we can use this drug, which is already on the market, to target BDNF." That is a mouse experiment with an existing compound, not evidence that any approved drug treats breast cancer this way. Repurposing requires its own trials.
A Human Signal, and Its Limits
The team checked whether the pattern appears in people by analyzing patient data. Tumors with higher levels of macrophages and BDNF were associated with poorer survival.
That is an association in human tissue, consistent with the mouse mechanism but not proof of it. Prior work has found the relationship between macrophages and breast cancer outcomes to be genuinely complicated, with subtype, location, and signaling context all appearing to matter, and with tumors actively recruiting macrophages through several parallel routes.
The headline nobody should take from this is that nerves cause cancer. Nerves do not initiate malignancy. This line of work describes a tumor that has already formed, reshaping its surroundings, with the nervous system among the systems it recruits.
Why Nerves Might Be Suppressing the Immune Response
Cox's working hypothesis is that the tumor-infiltrating nerves are immunosuppressive. "If we can stop the nerves from growing in the first place, maybe we can boost the immune response to help fight the cancer," she said.
Triple-negative breast cancer is the reason any of this is being pursued urgently. It lacks the estrogen and progesterone receptors and the HER2 protein that make other breast cancers targetable, leaving surgery, chemotherapy, and limited immunotherapy as the main options.
Cox says the next questions are how nerves drive growth, with existing evidence pointing to nerves encouraging blood vessel formation and to tumor cells traveling along nerve fibers to escape the primary site. She also plans to test whether the same mechanism operates in high-grade ovarian cancer, another disease with limited options and a similar pattern of dense innervation. The stated destination is not a nerve drug for its own sake. "Ultimately, we want to turn the anti-tumor immunity back on in cancer patients so their own immune systems can reject the tumors," she said.
Nothing here changes treatment. This is mouse work with a supporting human correlation, no clinical trial, and no approved therapy. Anyone facing a triple-negative diagnosis should discuss current standard care and trial eligibility with their oncology team.
Key Questions Answered
What did the study find?
That tumor-associated macrophages, not tumor cells, are the critical source of BDNF drawing nerves into triple-negative breast tumors in mice.
Does this mean nerves cause cancer?
No. Nerves do not initiate malignancy. The research describes an existing tumor recruiting nerves into its environment to support growth.
How strong is the evidence?
Strong within the mouse model. Tumors could not grow without immune-derived BDNF, and restoring normal macrophages restored both nerve growth and tumor growth.
What is the human evidence?
An analysis of patient data found that tumors with higher macrophage and BDNF levels were associated with poorer survival. That is an association, not proof of a mechanism.
Is there a drug for this?
Researchers used an existing marketed compound to block BDNF signaling in mice. No approved therapy targets tumor innervation in breast cancer, and repurposing would require clinical trials.
Why triple-negative breast cancer?
It lacks the estrogen receptor, progesterone receptor, and HER2 protein that make other breast cancers targetable, so treatment options are narrower and new mechanisms matter more.
